- Trial phase
- Phase 1
- Time to market
- Estimated 6-8+ years, if successful. Still in Phase 1; inflammation/immunology programs typically take years to reach approval.
- Why 4/10
- GS-6791 is an early-phase (Phase 1) partnered program with Gilead. No hard dated catalyst (PDUFA or pivotal readout) is scheduled in the next ~12 months. The next milestone is Phase 1 healthy-volunteer safety data, but no timeline has been provided. Nurix's dominant value driver is its lead BTK degrader bexobrutideg (backed by a $700M Roche deal), not this IRAK4 program. Score reflects early-stage partnered asset without a near-term binary catalyst.
GS-6791 is a minor piece of the NRIX story. Investors should watch for Phase 1 healthy-volunteer safety/PK data from Gilead, which could inform Nurix's decision on opting into a 50/50 U.S. profit share. However, the stock's near-term trajectory is dominated by bexobrutideg (BTK degrader) and the Roche collaboration, GS-6791 is not a standalone catalyst for NRIX.
Price Chart
Executive Summary
GS-6791 (also known as NX-0479) is an oral IRAK4 protein degrader being developed by Gilead Sciences under a collaboration with Nurix Therapeutics (Nasdaq: NRIX). It is the first drug candidate to come out of the Nurix-Gilead 2019 discovery collaboration. After Gilead exercised its option in March 2023, Gilead has led all development. The FDA cleared the IND in April 2025, and a Phase 1 SAD/MAD trial in healthy volunteers began in Q2 2025. Nurix retains an option to co-develop and share U.S. profits 50/50 after Phase 1 data readout. The drug targets inflammatory conditions like rheumatoid arthritis and atopic dermatitis. For NRIX investors, GS-6791 is an early-stage partnered program, less impactful to the stock than Nurix's lead BTK degrader bexobrutideg, which recently secured a $700M Roche collaboration.
How It Works
GS-6791 is an oral drug that degrades IRAK4, a key protein inside immune cells that acts like a master switch for inflammation. By destroying IRAK4 rather than just blocking it temporarily, the drug aims to shut down inflammatory signals more thoroughly and durably. This could help treat diseases driven by excessive inflammation, such as rheumatoid arthritis and atopic dermatitis (eczema).
Trial Status
FDA cleared the IND in April 2025. Gilead initiated a Phase 1 single- and multiple-ascending dose (SAD/MAD) study in healthy volunteers in Q2 2025. Preclinical data were presented at EADV in September 2025. The Phase 1 trial is ongoing. No clinical data readout has been publicly disclosed yet.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 SAD/MAD healthy-volunteer safety, tolerability, PK/PD data readout, no firm date disclosed (likely late 2025 or 2026).
- Nurix's decision on whether to opt into 50/50 U.S. profit share and co-development with Gilead (timed after Phase 1 data).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Nurix Therapeutics, Inc. PRESS-RELEASE NRIX ·Originating report